Amgen Inc.

At least 13 companies described preclinical KRAS degraders at the meeting

An analysis of the targets companies are pursuing to retain muscle while losing fat

German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition

Seven new products get positive opinions in April

FDA has at least seven more target action dates coming up in April

AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition

Seven of 11 $1B+ immunology acquisitions focused on two diseases

BioCentury’s roundup of translational innovations also includes boosting T cell antitumor activity via fructose, and a new Parkinson’s risk gene

San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics

Plus: CEO Edward Kayne steps down at Stoke, and updates from Collegium, Pyxis, Recursion and Tonix